NEWS

A pragmatic way forward in chemical safety assessment

In a recent paper, FREIA partners Terje Svingen (DTU) and Pauliina Damdimopoulou (KI) propose an approach to speed up the development and acceptance of mechanistic descriptions that are used by chemical safety assessors and regulators.

Adverse Outcome Pathways (AOPs) are a way to organise scientific knowledge and describe how a stressor – such as exposure to an endocrine disrupting chemical – can lead to a harmful health effect through a chain of linked events. The use of AOPs is gaining wide acceptance and will help to support chemical safety assessors and regulators.

Yet, only a few AOPs are thoroughly evaluated and endorsed by the Organisation for Economic Co-operation and Development (OECD), which clearly hampers their regulatory use. A major hurdle is the immense amount of work that has to be put into the development of an AOP. “Putting together the information for one key event relationship (the link between two sequential events in an AOP – red.) took me about three months altogether”, explains Eleftheria Panagiotou, PhD student involved in this work.

“We propose to focus more on smaller building blocks and rely more on existing common knowledge”, says lead author Terje Svingen. The approach will make it more attractive for scientists to contribute to AOPs, because in this way, they can focus on their own expertise and don’t have to be an expert on all facets of an AOP from molecular interactions to health effects.

Moreover, a description of a smaller AOP building block makes an excellent paper to be submitted for peer-review. Besides the scientific merit, publishing the building blocks has the added advantage that external peer-reviewers have already critically evaluated the information. This may stimulate faster endorsement of AOPs by the OECD. “It is our hope that our proposed approach will increase the pace at which the AOP knowledge base is populated with endorsed AOPs, which will certainly improve chemical safety assessment processes.”, according to the authors of this paper.

Reference

Terje Svingen, Daniel L. Villeneuve, Dries Knapen, Eleftheria Maria Panagiotou, Monica Kam Draskau, Pauliina Damdimopoulou, Jason M O’Brien. A pragmatic approach to Adverse Outcome Pathway (AOP) development and evaluation. Toxicological Sciences, kfab113, https://doi.org/10.1093/toxsci/kfab113 Published: 17 September 2021

2nd Annual EDC Forum report and recordings now available

The Second Annual Forum on Endocrine Disruptors took place virtually on 17-18 December 2020. A full report of the conference and the conference recordings are now available.

Read and listen how FREIA coordinator Majorie van Duursen presented challenges and opportunities to identify EDCs that are toxic to female reproduction.

The objective of the Second Annual Forum is to present the actions on endocrine disruptors in the Chemicals Strategy for Sustainability, published as annex to this Strategy, on which the actions are based. In addition, this forum will serve as a platform for policy makers and stakeholders to discuss follow-up actions. Finally, recent developments on endocrine disruptors (research projects funded, European initiatives…) were discussed.

Book review: “Count Down – How our modern world is threatening sperm counts, altering male and female reproductive health, and imperiling the future of the human race” by Dr. Shanna Swan

Renowned epidemiologist Dr. Shanna Swan is releasing a new book alerting about the threats posed by hormone disrupting chemicals and our modern environment that are imperiling reproductive health, fertility, and the fate of humankind. Building on more than 25 years of research on the associations between exposure to environmental pollutants and health effects, “Count Down – How our modern world is threatening sperm counts, altering male and female reproductive development and imperiling the future of the human race” is a clarion call for more protective public policies and changes in our modern way or living. 

Count Down paints a bleak but important picture about how chemicals in our environment and unhealthy lifestyle practices are disrupting our hormonal balance and causing varying degrees of reproductive havoc. These trends are contributing to the current decline in sperm count, harm fertility, and are leading to long-term and cross-generational health problems even after one has left the reproductive years.

Her 2017 publication of a meta-analysis, which grabbed media attention across the world, found that among men from North America, Europe and Australia, sperm concentration had declined more than 50% in less than 40 years [3]. Dr. Swan already presented EU policy-makers with epidemiological evidence about the impacts of endocrine disrupting chemicals (EDCs) on human health in 2012 – nearly a decade ago [4]. Despite the European Union taking steps to create safe and toxic-free environments, to date these findings have yet to be translated into tangible and health-protective change to reverse current trends.

While associations between exposure to endocrine disrupting chemicals (EDCs) and adverse reproductive health outcomes are increasingly well-documented, few research projects are currently addressing them. The FREIA project – Female Reproductive toxicity of EDCs: a human evidence-based screening and Identification Approach – has started exploring just how endocrine disrupting chemicals (EDCs) affect female reproductive health, and aims at developing test methods to identify EDCs that do so [5]. Elsewhere, the ATHLETE project is aiming to better understand how the environment can impact human health, from pregnancy to adolescence, by studying the human exposome [6]. Meanwhile health groups like the Health and Environment Alliance (HEAL) and federations of professionals such as the Federation of Gynecology and Obstetrics (FIGO) are spreading more awareness around exposure to toxic chemicals during and after pregnancy, and other vulnerable life stages [7].

Count Down: How our modern world is threatening sperm counts, altering male and female reproductive development and imperiling the future of the human race is a wake-up call and a must-read for anyone concerned about the future of our collective environmental health. The book features infographics that are available upon demand, including the infographic ‘Low Doses Matter’ published by TEDX – The Endocrine Disruption Exchange and HEAL in 2019 [8].

This article is re-posted from the HEAL website. View the original post here.

Notes to editor:

  1. “Count Down – How our modern world is threatening sperm counts, altering male and female reproductive development and imperiling the future of the human race”: https://www.shannaswan.com/countdown
  2. Dr. Swan will present her new book during a webinar hosted by the Collaborative on Health and the Environment’s EDC Strategies Partnership on February 23rd, 1PM US Eastern / 7PM Central European time:  https://www.healthandenvironment.org/webinars/96557
  3. Meta-analysis finds that among men from North America, Europe and Australia, sperm concentrations has declined more than 50% in less than 40 years (2017) https://www.env-health.org/etiam-posuere-ipsum-mi-2-2-2/
  4. https://www.env-health.org/2012-04-12_summary-of-swan-points_final/
  5. The Female Reproductive Toxicity of EDCs Project – A Human Evidence-Based Screening and Identification Approach (FREIA) aims to improve the identification of chemicals that affect women’s health via disruption of the hormone system. HEAL is one of 11 partners of the FREIA project: https://www.env-health.org/freia-female-reproductive-toxicity-of-edcs/
  6. The ATHLETE project is a European-funded research project that aims to better understand and prevent health effects of numerous environmental hazards and their mixtures, starting from the earliest stages of life. ATHLETE brings together 22 partners, including HEAL: https://athleteproject.eu/
  7. Infographic: ‘10 tips to avoid toxic chemicals during and after pregnancy’ by FIGO, UCSF and HEAL https://www.env-health.org/figo-ucsf-and-heal-share-10-tips-to-avoid-toxic-chemicals-during-and-after-pregnancy/For further examples of HEAL’s infographics about health-harming chemicals, please visit our joint project with the Belgian Mutualités Libres: https://www.env-health.org/mutualites-libres-and-heal-launch-infographic-illustrating-10-tips-to-avoid-endocrine-disruptors-in-and-around-your-home/
  8. Infographic: ‘Low Doses Matter – Everyday exposures to EDCs contribute to modern health epidemics’ by TEDX – The Endocrine Disruption Exchange and the Health and Environment Alliance (HEAL) https://www.env-health.org/infographic-low-doses-matter/

Join the second FREIA webinar

EDC IDENTIFICATION: HOW DOES IT WORK?

27 October 2020, 15PM in Brussels.

In 2018, the European Commission adopted criteria to assess whether a biocide or pesticide is an endocrine disruptor. A guidance document was written on how to do this in practice. FREIA partner Julie Boberg (Technical University of Denmark) will explain the process of ED identification, using butylparaben as an example. 

Butylparaben is often used in cosmetics to prevent microbial growth. It is on the candidate list of substances of very high concern of the European Chemicals Agency for its endocrine disrupting properties.

Not only will Dr Boberg show that butylparaben has more negative effects on reproduction than previously thought. It is also a great example that current criteria and EDC identification tools may also be suitable for other chemical regulations.

This webinar is organised by the FREIA project, with support from the Health and Environment Alliance (HEAL). Participation is free. For more details, please contact info@freiaproject.eu

Participation is free. You can register here.

A new FREIA newsletter is out

The October 2020 FREIA newsletter is released today. We are proud to share some of our research updates, recently published papers, future activities, and introduce you to our talented researcher Hanna Johansson.

Despite the covid-19 pandemic, the FREIA team has done a great job to continue working towards the FREIA goal: provide better test methods for identification of EDCs harmful for female reproductive health.

We warmly invite you to read our latest newsletter or subscribe to future newsletters at www.freiaproject.eu/subscribe

FIGO, UCSF and HEAL share 10 tips to avoid toxic chemicals during and after pregnancy

The Federation of Gynecology and Obstetrics (FIGO), the University of California – San Francisco (UCSF) and the Health and Environment Alliance (HEAL) have launched  easy-to-use infographics for obstetricians, gynecologists and health groups to create awareness around toxic chemicals and pregnancy in a one-week social media campaign.

Exposure to toxic chemicals before, during and after pregnancy jeopardizes women’s health. The infographics launched today (in English, French, German and Spanish) illustrates 10 tips that women can use for individual lifestyle and routine changes in efforts to avoid health-harming substances, as well as advice for policymakers.

You can download the infographics here on the HEAL website.

New scientific study highlights non-monotonic dose-response curves and low-dose effects of bisphenol A

A new scientific study, undertaken as part of the US CLARITY-BPA project [1], developed a quantitative assessment of the effects of bisphenol A (BPA) exposure on mammary gland development and found a consistent pattern of non-monotonic dose response relationships [2] on a set of over 90 measurements. This demonstrates a causal relationship between exposure to BPA and the health effects observed.

“A combined morphometric and statistical approach to assess non-monotonicity in the developing mammary gland of rats in the CLARITY-BPA study” [3] was published today in the journal Environmental Health Perspectives.

The study is striking because it uses both novel and standard quantitative as well as standard semiquantitative methods to analyse the effects of BPA exposure over critical windows of development: one set of experiments from gestation to weaning, and another one from gestation until tissue harvesting up to 6 months of age. Both quantitative methods reveal clear non-monotonic dose response curves, with the administration of lower doses resulting in larger effects on the development of the mammary gland at all-time points. In addition, the study tested several hypotheses regarding whether BPA and ethinyl oestradiol (EE2, a reference estrogen) produced similar effects, and compared their respective dose-response curves.

Striking findings of the study include the following: 

  • Clear statistical evidence of non-monotonic dose response curves of developmental exposure to BPA for multiple measurements;
  • break point in the dose-response curves between doses of 25 and 250 ug BPA/kg body weight/day;
  • Occurrence of non-monotonic dose response curves at all ages of the animals studied, with the same breaking point;
  • Using the same set of animals as the CLARITY-BPA core study, a statistical demonstration that the low-dose effects of BPA (e.g. mammary cancer already at 2.5 ug/kg/day) observed in the CLARITY-BPA core study are due to a causal relationship between the dose of BPA administered and its effect. This provides a counterpoint to the earlier statements according to which the low-dose effects observed were due to random events.
  • Clear statistical evidence that different estrogens can produce either similar or very different effects, depending on the endpoints being measured. This contradicts the hypothesis that BPA and ethinyl estradiol would always have similar effects.
  • Clear added-value of the novel methodology used for the mammary gland in detecting the non-monotonicity of the dose-response curve and expanding the number of properties observed in mammary glands.
  • Clear illustration of the importance of developing and using statistical methods that are appropriate to detect the non-monotonic dose responses that are relevant for endocrine disruptors, since they are not caught adequately by tools developed to exhibit linear responses.

The quantitative method elaborated in the study responds to one of the CLARITY-BPA objectives to develop software tools fit for performing automatic evaluation of aspects of the mammary glands and determining dose-response curves. In other words, this method allows to assess several aspects of mammary gland morphology that are not accessible by manual assessments.

The mammary gland has been considered a particularly sensitive endpoint for endocrine disruption, with measurable effects seen at low levels of exposure and earlier than cancer occurrence. Testing of this endpoint as part of animal studies is thus of particular relevance for the regulatory safety assessment of EDCs.

Natacha Cingotti, senior health and chemicals policy officer at the Health and Environment Alliance (HEAL) said: “This study is yet another confirmation that exposure to even low doses of bisphenol A can be harmful to health and that it is not possible to set safe doses of exposure to this widely-used endocrine disruptor. BPA should be fully banned from consumer products and food packaging, and the tolerable daily intake needs to be further reduced.” 

“As European institutions are drafting proposals for a revised framework to regulate endocrine disruptors, the promise to effectively protect people from their potential health effects must be based on the assumption that there are no safe levels of exposure, and that avoiding human exposure to such substances must be the top priority.”

A ‘questions and answers’ in relation to this study have been made available for download here.

Background

Bisphenol A is registered in Europe as a high-volume chemical and it is used in the production of numerous plastic products or coatings that are applied in a myriad of applications for packaging or industrial processes [4]. Exposure to BPA has been linked to several significant health conditions such as reproductive disorders, increased cancer risks (e.g. breast and prostate cancer), metabolic disorders such as obesity and diabetes, altered immune system, effects on the nervous, immune, and effects on brain development and behaviour, including in children.

BPA is on the European Chemical’s Agency (ECHA)’s candidate list of substances of very high concern, due to its reproductive toxicity and its endocrine disrupting properties for human health and the environment [5].

The European Food Safety Authority (EFSA) is currently re-assessing the potential hazards of BPA in food. The conclusion of its assessment is expected later in 2020 [6].

Notes

This article is re-posted from the HEAL website. View the original post here.

[1] The CLARITY-BPA project is a US research project designed in 2012 to examine differences between academic-led studies and test results and those carried out under Good Laboratory Practices, which are heavily relied on by regulatory agencies, when it comes to the safety assessment of bisphenol A. Bringing together the National Institute of Environmental Health Sciences, the US National Toxicology Program, the US Food and Drug Agency, as well as independent academics, the aim of the project was to overcome recurring differences in test results about the safety of bisphenol A

[2] Non-monotonic dose response curves (NMDRs) describe a dose-response relationship characterized by a curve, of which slope changes direction within the range of tested doses. For more information, see: https://www.endocrine.org/advocacy/position-statements/endocrine-disrupting-chemicals ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6137554/pdf/10.1177_1559325818798282.pdf ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429934/pdf/12940_2014_Article_851.pdf

[3] Maël R. Montévil et al. “A combined morphometric and statistical approach to assess non-monotonicity in the developing mammary gland of rats in the CLARITY-BPA study”, Environmental Health Perspectives,  https://dx.doi.org/10.1289/EHP6301

[4] https://echa.europa.eu/substance-information/-/substanceinfo/100.001.133

[5] https://echa.europa.eu/candidate-list-table/-/dislist/details/0b0236e180e22414

[6] EFSA, BPA update: working group to start reviewing new studies, 4 September 2018, https://www.efsa.europa.eu/en/press/news/180904

FREIA FACTSHEET out now!

With great pleasure, we announce the release of our first FREIA factsheet and infographic on endocrine disrupting chemicals (EDCs) and women’s reproductive health. Both are available in multiple languages.

It is beyond a doubt that endocrine disrupting chemicals (EDCs) impact the health of humans and the environment globally. Surprisingly, we still don’t know exactly how EDCs can harm female reproductive health.

With this factsheet and infographic, we hope to help people understand better what EDCs are and the impact EDCs have on women’s health“, says Majorie van Duursen – coordinator of FREIA. “It also addresses where the challenges lie with regulating EDCs in Europe and how FREIA aims to contribute to protective chemical regulations“.

The factsheet was written together with Health and Environment Alliance (HEAL) and is endorsed by the International Federation of Gynecology and Obstetrics (FIGO) and the International Federation of Fertility Societies (IFFS).

We are extremely happy with such strong partners in communication and advocacy on women’s health issues. It shows the wide-spread concern about environmental impact on women’s health, beyond the academic community. By joining forces we can reach a broader audience and create more awareness for this pressing matter“, according to Van Duursen.

EC asks input from public on EDCs

As part of their strategy for endocrine disruptors, the European Commission will take a cross-cutting look at the approach to endocrine disruptors’ assessment and management in a broad range of legislation.

This “Fitness Check”  includes two public consultations: a public consultation (designed from a citizen’s perspective) and a stakeholder consultation (designed for stakeholders and experts).

You can have your say! The online survey can be found here and is open for comments until 31 January 2020.

FREIA is well on track

The FREIA consortium met on 29-30 October 2019 to share updates on the work progress. All partners were represented by one or more researchers at the meeting that was hosted by VU Amsterdam.

The first results from the laboratory experiments and computational modelling were presented to the partners. There was some exchange of views on which EDCs should be measured in the human samples that are available within FREIA.

Coordinator Majorie van Duursen: “it was so great to see the enthusiasm and dedication of this wonderful group. We are well on schedule with the planned work”.

Besides the experimental work, the FREIA consortium is working on a review paper to describe how EDCs cause female reproductive health issues. The paper is expected to be published early 2020. Future activities to communicate FREIA goals were also on the agenda. Many great ideas were formed on newsletters and webinars.

All in all, it was a very productive meeting with great promise to achieve FREIA goals.